NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Surrozen, Inc. (SRZN) Stock Analysis

Surrozen, Inc. (SRZN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SRZN

$22.76

+$0.22 (+0.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SRZN with… →

SRZN Key Statistics

As of Sep 4, 2026
Trading
Open
$22.34
Previous Close
$22.54
Day's Range
21.54–22.90
52-Week Range
11.25–35.00
Volume
150.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$267.51M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
23.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−40.51
Financials (FY)
Revenue (FY)
$3.48M−67.37%
Net Income (FY)
−$242.03M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.75M
1-Year Return
+82.81%
Dividend and dates
Avg Volume
211.29K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SRZN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.71%
2025+57.49%
2024+52.66%
2023+7.67%
2022−90.96%
2021−36.30%

As of September 4, 2026.

SRZN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.48M−$242.03M−6960.8%
2024$10.66M−$63.56M−596.6%
2023$0.00−$43.04M—
2022$12.50M−$36.00M−288.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.48M—−$42.09M−$242.03M−6960.8%
2024$10.66M—−$25.54M−$63.56M−596.6%
2023$0.00—−$43.03M−$43.04M—
2022$12.50M—−$44.34M−$36.00M−288.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SRZN Valuation vs Biotechnology Median

Median of 656 stocks
MetricSRZNBiotechnology medianvs median
P/S ratio23.2415.2652% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Surrozen, Inc. (SRZN) is capitalised at $267.51M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 44.

The most recent close on file for SRZN is $22.76, dated September 4, 2026. That is +$0.22 (+0.98%) against the previous close. Over the past 52 weeks the price has ranged from $11.25 to $35.00. The latest close sits 102.31% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.48M. That is −67.37% against the prior fiscal year, when revenue was $10.66M. The same year closed with a net loss of $242.03M. The reported profit margin is 0%. Trailing earnings per share are −40.51.

Across the 4 fiscal years on file, revenue moves from $12.50M in 2022 to $3.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 23.24 times revenue. On price-to-sales that is 52.26% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +82.81%. Across 5 years the annualized return works out at −26.84%. The reported beta is 0.56. Daily returns over the trailing 5 years annualize to a volatility of 97.3%.

Growth & Income

The record shows no dividend for SRZN.

The strongest complete calendar year on file is 2025 at +57.49%; the weakest is 2022 at −90.96%. Of the 5 complete calendar years on file, 3 finished higher. 2026 is still running; the price is +0.71% year to date.

Peer Comparison

Surrozen, Inc. (SRZN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Surrozen, Inc. SRZN $267.51M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Surrozen, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Surrozen, Inc.

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Visit website →